ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

ANIK Anika Therapeutics Inc

27.59
0.00 (0.00%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Anika Therapeutics Inc NASDAQ:ANIK NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 27.59 26.70 28.64 28.1899 27.53 27.91 56,826 05:00:04

Anika to Issue First Quarter 2020 Financial Results and Business Highlights on Thursday, May 7

23/04/2020 9:05pm

Business Wire


Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Anika Therapeutics Charts.

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its first quarter 2020 financial results after the close of the market on Thursday, May 7, 2020 and hold its investor conference call on the same day, Thursday, May 7, 2020, at 5:00 p.m. ET to discuss its financial results, business highlights, and outlook.

The conference call can be accessed by dialing 1-855-468-0611 (toll-free domestic) or 1-484-756-4332 (international). A live audio webcast will be available in the "Investor Relations" section of Anika's website, www.anikatherapeutics.com. An accompanying slide presentation also can be accessed via the Anika Therapeutics website. The call will be archived and accessible on the same website shortly after its conclusion.

About Anika Therapeutics, Inc.

Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated joint preservation and regenerative therapies company based in Bedford, Mass. Anika is committed to delivering therapies to improve the lives of patients across a continuum of care from osteoarthritis pain management to joint preservation and restoration. The company has more than two decades of global expertise commercializing more than 20 products based on its proprietary hyaluronic acid (HA) technology platform. For more information about Anika, please visit www.anikatherapeutics.com.

For Investor Inquiries: Anika Therapeutics, Inc. Sylvia Cheung, 781-457-9000 Chief Financial Officer investorrelations@anikatherapeutics.com

For Media Inquiries: W2O Group Jeremy Berrington, 312-241-1995 jberrington@w2ogroup.com

1 Year Anika Therapeutics Chart

1 Year Anika Therapeutics Chart

1 Month Anika Therapeutics Chart

1 Month Anika Therapeutics Chart

Your Recent History

Delayed Upgrade Clock